Organogenesis initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Organogenesis with an Overweight rating and $5 price target. Organogenesis is a commercial-stage regenerative medicine company focused on the development and sale of products for the advanced wound care and surgical and sports medicine markets, the analyst tells investors in a research note. The firm holds a favorable view of the estimated $24B advanced wound care and surgical and sports medicine markets and believes the company’s offerings are differentiated and protected given their strong clinical data. It finds the stock attractively valued at current levels.